Peptide
Romiplostim (Nplate)
Romiplostim is a recombinant Fc-peptide fusion protein thrombopoietin receptor agonist. FDA-approved 2008 for chronic ITP, 2018 for pediatric ITP. Phase 3: 88% overall platelet response vs 14% placebo in non-splenectomized patients. Durable response in 52% pediatric patients vs 10% placebo. Weekly SC injection maintains platelets ≥50,000/μL.
- Updated
- How we grade
- 58 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 1
- Outcomes
- 10
- Graded outcomes
- 4312
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- Bleeding ReductionImproves (the measure goes down)
- Durable Platelet ResponseImproves (the measure goes up)
- Overall Platelet ResponseImproves (the measure goes up)
Safety notes in the studies
- Safe long-term with no increased thrombosis or malignancy risk.
Studies cited
58 studies from PubMed
- Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.
- Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment.
- Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
- Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA.
- Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis.
- Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.
- Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.
- Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China
- Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature.
- Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management.
- Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings.
- A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. coli.
- Survival and Hematologic Benefits of Romiplostim After Acute Radiation Exposure Supported FDA Approval Under the Animal Rule.
- Romiplostim use in pregnant women with immune thrombocytopenia.
- Romiplostim drug presence in pregnancy and lactation.
- Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database.
- Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia.
- Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial.
- Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
- Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies.
- Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of a Romiplostim Biosimilar in Chronic Refractory Immune Thrombocytopenic Purpura (ITP) Patients.
- Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review.
- A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.
- Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia.
- Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.
- A Review of Romiplostim Mechanism of Action and Clinical Applicability.
- Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP).
- Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry.
- Romiplostim (Nplate(®)) as an effective radiation countermeasure to improve survival and platelet recovery in mice.
- Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description.
- Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial.
- Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry.
- Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
- Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
- Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report.
- Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy.
- Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
- Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
- Efficacy of romiplostim in the treatment of ITP in children: a meta-analysis.
- Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study
- Romiplostim for management of chemotherapy-induced thrombocytopenia.
- Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
- Romiplostim-induced myelofibrosis.
- Romiplostim: a review of its use in immune thrombocytopenia.
- The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
- Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
- Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial
- The development of romiplostim for patients with immune thrombocytopenia.
- Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)
- Romiplostim or standard of care in patients with immune thrombocytopenia
- Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.
- Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
- Romiplostim management of immune thrombocytopenic purpura.
- Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
- Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal.
- Romiplostim in chronic immune thrombocytopenic purpura.
- Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
- AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP